Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Aeglea BioTherapeutics Inc.
DescriptionEngineered human enzyme that is designed to degrade homocysteine in the circulation
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPreclinical
Standard Indication Metabolic (unspecified)
Indication DetailsTreat homocystinuria
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today